Does AMIX pay a dividend and is it safe?

Autonomix Medical Inc. (AMIX) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Stock Ratings / Health Care / AMIX / dividends

XAIR (30) CODX (29) ICCM (33) WOK (51) ⌘ Pro Terminal →

Autonomix Medical Inc. (AMIX) Dividend Safety Gauge & 10-Year DRIP Compounder

Q: Where is AMIX trading relative to its 50-day, 200-day, and 52-week technical levels?

AMIX last traded at $1.68 (-7.18% on volume of 51,464 shares), positioning the stock -54.47% below its 50-day simple moving average ($3.69) and -74.93% below its 200-day simple moving average ($6.70). Across its 52-week range of $1.81 to $32.55, AMIX sits at the 0.0% percentile with a 14-day RSI of 25.4 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.47 to $1.89).

$1.68 -7.18% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.66

Autonomix Medical Inc. (AMIX) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $3.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on AMIX Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is AMIX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Autonomix Medical Inc. (NASDAQ: AMIX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $1.68 (-7.18% 1D, market cap $3.5M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, AMIX ranks #660 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does AMIX compare to XAIR and CODX in the Health Care sector?

▼

Within the Health Care sector (Medical/Dental Instruments), AMIX carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, XAIR (Beyond Air Inc.) holds a E grade (30/100 RQD, P/E 112.1x, ROIC -35.0%, cap $3.7M) and CODX (Co-Diagnostics Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $3.2M). Among the 5-stock peer group, XAIR leads on earnings multiple (112.1x) while AMIX leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for AMIX?

▼

Per AMIX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-03-31, CIK 0001617867), Autonomix Medical Inc. generated $47.7M in revenue (+47.0% YoY), -$16.7M in net income, and -$12.3M in free cash flow against $10.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.66 (-1.48%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-10.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AMIX)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (34/100 Composite)

🔍 WHY AMIX SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+9/20 pts (26% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 25.4 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$3.01-13.3% Next Q

Q2 (-2Q)

Grade E$2.61-20.7% Next Q

Q3 (-1Q)

Grade E$2.07-18.8% Next Q

Current

Grade E$1.68-8.7% Hist 90D α

Trajectory: D (42) → E (34)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a AMIX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While AMIX currently carries a cautious 34/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.69) and Max Pain ($1.76) forces dealer call-delta covering toward $34.18.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $AMIX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “AMIX Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”

YES 34%NO 66%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (6.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $19,307

Est. Year-10 Shareholder Yield: $348/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.7K

Yr 1

$11.4K

Yr 2

$12.2K

Yr 3

$13.0K

Yr 4

$13.9K

Yr 5

$14.8K

Yr 6

$15.8K

Yr 7

$16.9K

Yr 8

$18.1K

Yr 9

$19.3K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AMIX)

✓Walkthrough of AMIX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

AMIX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -78.54%🛡️ HOLDING TREND SUPPORT

2026-11-03O $2.04H $2.04L $1.68C $1.68VOL 135.4K

RES: $10.84SUP: $-0.14SMA50: $3.69SMA200: $6.70

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

AMIX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 AMIX Butterfly Map → + Track AMIX →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. +47.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on AMIX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for AMIX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for AMIX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AMIX)

Health Care Rank #660 of 1015 ⚔️ XAIR vs AMIX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (AMIX vs. XAIR, CODX, ICCM, WOK)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Autonomix Medical Inc. (AMIX) ranks #660 by composite RQD confidence (34/100, grade E) and #965 by equity capitalization ($3.5M). Within this direct 5-issuer industry benchmark cohort, XAIR leads on earnings valuation at 112.1x trailing P/E, while AMIX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. WOK currently holds the highest overall quantitative score in the immediate peer group at 51/100 (D) compared with AMIX at 34/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
AMIX ACTIVE Autonomix Medical Inc.	E	34/100	—	—	-35.0%	-7.18%	$3.5M	Benchmark Subject
XAIR Beyond Air Inc.	E	30/100	112.1x	3.3%	-35.0%	-1.34%	$3.7M	/xair-vs-amix →
CODX Co-Diagnostics Inc.	E	29/100	—	64.3%	-35.0%	-3.65%	$3.2M	/codx-vs-amix →
ICCM IceCure Medical Ltd.	E	33/100	—	36.3%	-35.0%	-3.14%	$3.0M	/iccm-vs-amix →
WOK WORK Medical Technology Group LTD (Class A)	D	51/100	—	—	—	0.00%	$4.5M	/wok-vs-amix →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2026-03-31 • CIK 0001617867 ↗

In its most recent audited fiscal period (FY2025, filed 2026-03-31), Autonomix Medical Inc. (AMIX) reported GAAP revenue of $47.7M (+47.0% vs. FY2024 revenue of $32.4M , and +41.6% cumulative change since FY2023) , GAAP net income of -$16.7M, operating cash flow of -$12.3M, and free cash flow of -$12.3M (-48.6% YoY). On the balance sheet, AMIX closed FY2025 with $10.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2026-03-31	$47.7M	-$16.7M	-$12.3M	-$12.3M	$10.2M	—
FY2024 (FY)	2025-03-31	$32.4M	-$11.4M	-$8.3M	-$8.3M	$12.0M	—
FY2023 (FY)	2024-03-31	$33.7M	-$15.4M	-$6.6M	-$6.6M	—	—

3. AMIX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is AMIX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does AMIX compare to XAIR and CODX in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for AMIX?

Where is AMIX trading relative to its 50-day, 200-day, and 52-week technical levels?

AMIX last traded at $1.68 (-7.18% on volume of 51,464 shares), positioning the stock -54.47% below its 50-day simple moving average ($3.69) and -74.93% below its 200-day simple moving average ($6.70). Across its 52-week range of $1.81 to $32.55, AMIX sits at the 0.0% percentile with a 14-day RSI of 25.4 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.47 to $1.89).

Direct Sub-Reports: AMIX RQD Cockpit AMIX 12M Forecast AMIX Earnings & Move AMIX Dividends & DRIP AMIX Insiders & 13F AMIX Whale Options AMIX Profit Sankey AMIX News & Why

ROARABLE RATING BRIEF • RQD 34/100 (E) ✓ SEC XBRL & RQD VERIFIED

AMIX — Autonomix Medical Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2026-03-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Autonomix Medical Inc. (AMIX) earns a live Roarable RQD composite score of 34/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.68 (-7.18% 1D, market capitalization $3.5M).

Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (9/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Autonomix Medical Inc. (AMIX) is a NASDAQ-listed issuer in the Health Care sector, operating in the Medical/Dental Instruments industry. The company is classified within this sector and industry. Reported revenue for FY 2025, FY 2024, and FY 2023 is — in each period which indicates no reported revenue in the periods provided.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2026-03-31), Autonomix Medical Inc. (AMIX) reported $47.7M in annual revenue (up from $32.4M in FY2024, +47.0% YoY) and -$16.7M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($33.7M revenue, -$15.4M net income) through FY2025, AMIX scaled operating cash flow to -$12.3M and free cash flow to -$12.3M, backed by $10.2M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (E • RQD 34/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.81 – $32.55 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The supply chain is NONE, with an empty list of butterfly links and an empty list of proprietary signals. The source data therefore does not identify upstream suppliers, downstream customers, or sector correlations. The one sector context available is that the company sits in Health Care / Medical/Dental Instruments. Second-order bottlenecks cannot be mapped from the supplied data.

Key Question #1: Can AMIX sustain or expand its — operating margin and -35.0% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $47.7M and free cash flow of -$12.3M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is AMIX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

AMIX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Autonomix Medical Inc. (AMIX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to AMIX Debate Forum (3) ↓

🟡 MARKET WIRE The Globe and Mail • 22h ago

Autonomix Medical, Inc. (AMIX) Receives a Buy from Maxim Group

The Globe and Mail report covering Autonomix Medical Inc. (AMIX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance UK • 1d ago

Autonomix Medical, Inc. (AMIX) Seasonal returns chart

Yahoo Finance UK report covering Autonomix Medical Inc. (AMIX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH kalkine.ca • 1d ago

Which USD 7 million medical-device developer fell 3.4 percent premarket to USD 3.65 after a 1-for-21 reverse split and a going-concern warning?

kalkine.ca report covering Autonomix Medical Inc. (AMIX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingKey • 1d ago

Most Active Stocks Today: U.S. Market

TradingKey report covering Autonomix Medical Inc. (AMIX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance UK • 1d ago

NeuroOne Medical Technologies Corporation (NMTC) stock price, news, quote and history

Yahoo Finance UK report covering Autonomix Medical Inc. (AMIX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

Allurion Technologies Inc. (ALUR) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada report covering Autonomix Medical Inc. (AMIX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE kalkine.ca • 1d ago

Which of four small caps facing insider loans, delisting deadlines and a Bitcoin-funded balance sheet has the most pressing test?

kalkine.ca report covering Autonomix Medical Inc. (AMIX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

908 Devices Inc. (MASS) Seasonal Returns Chart

Yahoo! Finance Canada report covering Autonomix Medical Inc. (AMIX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

AMIX Bull vs. Bear Conversation Board — What's Your Call at $1.68?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON AMIX 🐻 33% BEARISH CONVICTION

DE DeepValue_CFA RQD DEBATE OPENER • Institutional Buy-Side 🐂 BULLISH 🎯 Target: $2.15 (+18.8%)

📌 Pinned Debate

The stock trades at a $4.0M market cap with a 52-week low of $1.81, leaving room for a rerating if the company's cash balance of $9.9M

Don't sleep on AMIX's setup in Health Care. The stock trades at a $4.0M market cap with a 52-week low of $1.81, leaving room for a rerating if the company's cash balance of $9.9M supports a financing path.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (34/100) backs up the fundamental quality.

CapAlloc_Nerd 🐂 BULL

@MeanReversion_88 Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Medical/Dental Instruments. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

ME MeanReversion_88 RQD DEBATE OPENER • Quantitative Statistical Arb 🐻 BEARISH 🎯 Target: $1.39 (-23.2%)

Spot @ $1.81

Reported revenue is $0.0M across FY 2023 to FY 2025 while losses persist, the Piotroski F-Score is 2/9, and a going-concern warning is

I respect the product at Autonomix Medical Inc., but the stock at $1.81 is a different story. Reported revenue is $0.0M across FY 2023 to FY 2025 while losses persist, the Piotroski F-Score is 2/9, and a going-concern warning is cited in the news feed.. FCF yield is 0.0% and RQD sits at 34/100 (E) — why pay up here when you can wait for next quarter's numbers?